Contents

Current Molecular Medicine, Volume 3 - Number 5

Preface

, 3(5): ii

B. Dean


DOI: 10.2174/15665240103030500ii




Schizophrenia and Bipolar Affective Disorder: Perspectives for the Development of Therapeutics

, 3(5): 393 - 407

S. Sundram, P. R. Joyce and M. A. Kennedy


DOI: 10.2174/1566524033479708




From Pharmacotherapy to Pathophysiology: Emerging Mechanisms of Apolipoprotein D in Psychiatric Disorders

, 3(5): 408 - 418

E. A. Thomas, D. L. Copolov and J. G. Sutcliffe


DOI: 10.2174/1566524033479681




Muscarinic Receptors in Schizophrenia

, 3(5): 419 - 426

B. Dean, F. P. Bymaster and E. Scarr


DOI: 10.2174/1566524033479654




Cellular Pathology in the Dorsolateral Prefrontal Cortex Distinguishes Schizophrenia from Bipolar Disorder

, 3(5): 427 - 436

L. D. Selemon and G. Rajkowska


DOI: 10.2174/1566524033479663




The Use of Microarrays to Characterize Neuropsychiatric Disorders: Postmortem Studies of Substance Abuse and Schizophrenia

, 3(5): 437 - 446

E. Lehrmann, T. M. Hyde, M. P. Vawter, K. G. Becker, J. E. Kleinman and W. J. Freed


DOI: 10.2174/1566524033479690




Proteomics in the Discovery of New Therapeutic Targets for Psychiatric Disease

, 3(5): 447 - 458

Hans Voshol, Marc J. Glucksman and Jan van Oostrum


DOI: 10.2174/1566524033479645




Neurodevelopmental Animal Models of Schizophrenia: Effects on Prepulse Inhibition

, 3(5): 459 - 471

M. Van den Buuse, B. Garner and M. Koch


DOI: 10.2174/1566524033479627




Neurodevelopment and Mood Stabilizers

, 3(5): 472 - 482

A. J. Harwood


DOI: 10.2174/1566524033479672




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science